
Biography not available yet.
Events

18
Sep
2025
Seminar
Past
External
Defining pathogenic mechanisms of Friedreich’s ataxia to reveal opportunities for therapeutic intervention
Jill Napierala
Abstract Friedreich’s ataxia (FRDA) is an autosomal recessive neurodegenerative disease caused by mutations in the frataxin gene (FXN) that reduce […]
Amphi 2 Bis (2nd floor), Faculté de Médecine Lyon-Est Rockefeller

08
Sep
2023
Seminar
Past
External
Understanding circuit-mediated vulnerability in SCA1
Pr Smita Saxena
Abstract Spinocerebellar ataxia type 1 (SCA1) is a fatal neurodegenerative disease caused by a polyglutamine (PolyQ) expansion in the Ataxin-1 […]
Amphi 3 bis

21
Feb
2020
Seminar
Past
External
Exploring neurofilament biology and autophagy in neuromuscular diseases:from Giant Axonal Neuropathy to Charcot-Marie-Tooth diseases
Pascale BOMONT
Abstract Our group is interested in inherited neuromuscular diseases, and in particular in axonal forms of Charcot-Marie-Tooth diseases. Our focus […]
Salle Médiathèque Paul ZECH
Projects
Type:
Category:
Towards a better understanding of the pathophysiology of Friedreich Ataxia (FA) and Cerebellar ataxia with CoQ10 deficiency (ARCA2).

Principal investigator
Hélène Puccio
Team: Fundamental and pathophysiological mechanisms implicated in ataxia
Identification and validation of biomarkers for FA and ARCA2

Principal investigator
Hélène Puccio
Team: Fundamental and pathophysiological mechanisms implicated in ataxia
Developing pre-clinical therapeutic approaches

Principal investigator
Hélène Puccio
Team: Fundamental and pathophysiological mechanisms implicated in ataxia
Publications
2025
mitoXplorer 3.0, A Web Tool for Exploring Mitochondrial Dynamics in Single-cell RNA-seq Data,
Journal of Molecular Biology.
2025
Muscle mTOR controls iron homeostasis and ferritinophagy via NRF2, HIFs and AKT/PKB signaling pathways,
Cell Mol Life Sci 2025 Apr; 82(1): 178.
2024
Epidermal maintenance of Langerhans cells relies on autophagy-regulated lipid metabolism,
Journal of Cell Biology.
2024
Hereditary Ataxias: From Bench to Clinic, Where Do We Stand?,
Cells.
2024
Omaveloxolone: a groundbreaking milestone as the first FDA-approved drug for Friedreich ataxia,
Trends in Molecular Medicine.
2024
A multiple animal and cellular models approach to study frataxin deficiency in Friedreich Ataxia,
Biochim Biophys Acta Mol Cell Res 2024 Oct; 1871(7): 119809.
2023
Recent Advances on Therapeutic Approaches for Friedreich’s Ataxia: New Pharmacological Targets, Protein, and Gene Therapy,
.
2022
Homozygous COQ7 mutation: a new cause of potentially treatable distal hereditary motor neuropathy,
Brain - A Journal of Neurology.
2022
Homozygous COQ7 mutation: a new cause of potentially treatable distal hereditary motor neuropathy,
Brain 2023 Aug; 146(8): 3470-3483.

